First Time Loading...

Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 1.58 USD Market Closed
Updated: Mar 29, 2024

Intrinsic Value

ADAP's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. [ Read More ]

The intrinsic value of one ADAP stock under the Base Case scenario is 3.4 USD. Compared to the current market price of 1.58 USD, Adaptimmune Therapeutics PLC is Undervalued by 54%.

Key Points:
ADAP Intrinsic Value
Base Case
3.4 USD
Undervaluation 54%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Adaptimmune Therapeutics PLC

Backtest ADAP Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ADAP stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Adaptimmune Poised for Near-Term Growth
2023-Q4 Earnings Call

Adaptimmune Poised for Near-Term Growth

In 2023, Adaptimmune transitioned through corporate restructuring and completed a merger with TCR² Therapeutics, laying the groundwork for commercial success in 2024 and beyond. The company submitted the Biologics License Application (BLA) for afami-cel, marking a pivotal milestone as the first engineered T-cell therapy for solid tumors. With the FDA currently reviewing afami-cel, Adaptimmune expects to launch with initial availability planned for Q4 2024, aiming for 600 to 700 patient treatments annually. Financial stability is foreseen, with $147 million in liquidity and anticipated payments from Genentech to fund operations into early 2026. Adaptimmune projects up to $400 million in peak sales from its sarcoma franchise, including the recovered lete-cel therapy.

Financials

Balance Sheet Decomposition
Adaptimmune Therapeutics PLC

Current Assets 207.6m
Cash & Short-Term Investments 146.9m
Receivables 46.9m
Other Current Assets 13.7m
Non-Current Assets 75.1m
PP&E 71.7m
Intangibles 330k
Other Non-Current Assets 3m
Current Liabilities 72.8m
Accounts Payable 8.1m
Accrued Liabilities 35.6m
Other Current Liabilities 29m
Non-Current Liabilities 170.3m
Other Non-Current Liabilities 170.3m
Efficiency

Earnings Waterfall
Adaptimmune Therapeutics PLC

Revenue
60.3m USD
Operating Expenses
-191m USD
Operating Income
-130.7m USD
Other Expenses
16.8m USD
Net Income
-113.9m USD

Free Cash Flow Analysis
Adaptimmune Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ADAP Profitability Score
Profitability Due Diligence

Adaptimmune Therapeutics PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Negative Revenue Growth Forecast
26/100
Profitability
Score

Adaptimmune Therapeutics PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

ADAP Solvency Score
Solvency Due Diligence

Adaptimmune Therapeutics PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
51/100
Solvency
Score

Adaptimmune Therapeutics PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADAP Price Targets Summary
Adaptimmune Therapeutics PLC

Wall Street analysts forecast ADAP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADAP is 3.84 USD with a low forecast of 1.01 USD and a high forecast of 9.45 USD.

Lowest
Price Target
1.01 USD
36% Downside
Average
Price Target
3.84 USD
143% Upside
Highest
Price Target
9.45 USD
498% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ADAP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ADAP Price
Adaptimmune Therapeutics PLC

1M 1M
+1%
6M 6M
+103%
1Y 1Y
+49%
3Y 3Y
-68%
5Y 5Y
-63%
10Y 10Y
-90%
Annual Price Range
1.58
52w Low
0.429
52w High
1.75
Price Metrics
Average Annual Return 57.42%
Standard Deviation of Annual Returns 224.06%
Max Drawdown -96%
Shares Statistics
Market Capitalization 390m USD
Shares Outstanding 246 824 992
Percentage of Shares Shorted 2.6%

ADAP Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

390m USD

Dividend Yield

0%

Description

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.

Contact

OXFORDSHIRE
Abingdon
60 Jubilee Avenue
+441235430000.0
https://www.adaptimmune.com/

IPO

2015-05-06

Employees

494

Officers

CEO, Principal Accounting Officer & Director
Mr. Adrian G. Rawcliffe
Chief Financial Officer
Mr. Gavin Hilary James Wood ACA, BA (Hons)
Chief Operating Officer
Mr. William C. Bertrand Jr., Esq., J.D.
Chief Medical Officer
Dr. Elliot Norry B.A., M.D.
Co-Founder & Chief Business & Strategy Officer
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.
Chief Scientific Officer
Ms. Joanna Brewer Ph.D.
Show More
VP of Corporate Affairs & Investor Relations
Dr. Juli P. Miller Ph.D.
Senior VP & General Council
Ms. Kerry Sharp
Senior Director of Corporate Communications
Dana Lynch
Chief Patient Supply Officer
Mr. John Lunger
Show Less

See Also

Discover More
What is the Intrinsic Value of one ADAP stock?

The intrinsic value of one ADAP stock under the Base Case scenario is 3.4 USD.

Is ADAP stock undervalued or overvalued?

Compared to the current market price of 1.58 USD, Adaptimmune Therapeutics PLC is Undervalued by 54%.